Natus Medical (BABY) Stock Price, News & Analysis

Company Overview

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $26.75 to $31.92
• 52-Week Range: N/A
• Volume: 22 shs
• Average Volume: 165,325 shs
• Market Capitalization: $1.12 billion
• P/E Ratio: 23.21
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Natus Medical Stock Analysis - MarketRank™

Natus Medical scored higher than 43% of companies evaluated by MarketBeat, and ranked 669th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Natus Medical.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 24.41%

Earnings Growth

Earnings for Natus Medical are expected to grow by 24.41% in the coming year, from $1.27 to $1.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Natus Medical is 23.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Natus Medical is 23.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.88.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BABY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Natus Medical does not currently pay a dividend.

Dividend Growth

Natus Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.19

Short Interest

There is no current short interest data available for BABY.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for BABY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Natus Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.65% of the stock of Natus Medical is held by insiders.

Percentage Held by Institutions

91.56% of the stock of Natus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BABY Stock Analysis - Frequently Asked Questions

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) issued its quarterly earnings results on Wednesday, October, 24th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.42 by $0.02. The company's quarterly revenue was up 6.5% on a year-over-year basis.

When did Natus Medical IPO?

Natus Medical (BABY) raised $9 million in an initial public offering (IPO) on Wednesday, March 8th 2023. The company issued 1,766,618 shares at a price of $5.00 per share.

What other stocks do shareholders of Natus Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Natus Medical investors own include Bristol-Myers Squibb (BMY), Meta Platforms (META), Starbucks (SBUX), Intel (INTC), Walt Disney (DIS), Gilead Sciences (GILD) and Activision Blizzard (ATVI).

Company Calendar

• Last Earnings: 10/24/2018
• Today: 11/23/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical Equipment
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:BABY
• CUSIP: 63905010
• CIK: 878526
• Web: www.natus.com
• Phone: 925-223-6700
• Fax: N/A
• Employees: 1,729
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $1.42
• Trailing P/E Ratio: 23.21
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,930,000.00
• Net Margins: -7.38%
• Pretax Margin: N/A
• Return on Equity: 10.79%
• Return on Assets: 6.57%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 1.70
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $530.89 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.39
• Book Value: $11.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,010,000
• Free Float: N/A
• Market Cap: $1.12 billion
• Optionable: Optionable
• Beta: 0.57